Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study

Simpson, David M.; Messina, John; Xie, Fang; Hale, M.

doi:10.1016/j.clinthera.2007.04.007

Cited by 87 publications

(70 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…59,60 Because of methodological problems, valid estimates for efficacy of the intervention could not be determined, but adverse event rates among both treated populations were common and similar (range 63% to 65%) (Class III).…”

Section: In the Adult Ed Patient With An Acute Exacerbation Of Noncanmentioning

confidence: 99%

Clinical Policy: Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department

Cantrill

Brown

Carlisle

et al. 2012

Annals of Emergency Medicine

215

172

View full text Add to dashboard Cite

This clinical policy deals with critical issues in prescribing of opioids for adult patients treated in the emergency department (ED). This guideline is the result of the efforts of the American College of Emergency Physicians, in consultation with the Centers for Disease Control and Prevention, and the Food and Drug Administration. The critical questions addressed in this clinical policy are: (1) In the adult ED patient with noncancer pain for whom opioid prescriptions are considered, what is the utility of state prescription drug monitoring programs in identifying patients who are at high risk for opioid abuse? (2) In the adult ED patient with acute low back pain, are prescriptions for opioids more effective during the acute phase than other medications? (3) In the adult ED patient for whom opioid prescription is considered appropriate for treatment of new-onset acute pain, are short-acting schedule II opioids more effective than short-acting schedule III opioids? (4) In the adult ED patient with an acute exacerbation of noncancer chronic pain, do the benefits of prescribing opioids on discharge from the ED outweigh the potential harms?

show abstract

Section: In the Adult Ed Patient With An Acute Exacerbation Of Noncanmentioning

confidence: 99%

Clinical Policy: Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department

Cantrill

Brown

Carlisle

et al. 2012

Annals of Emergency Medicine

215

172

View full text Add to dashboard Cite

show abstract

“…ized controlled trials evaluating fentanyl buccal tablet effectiveness have reported decreases in breakthrough pain intensity within 10 minutes of administration among patients with chronic low back pain [ 51 ] and chronic noncancer neuropathic pain [ 52 ]. Similarly, OTFC has been shown effective in treating chronic noncancer pain [ 53 ] and migraine pain [ 54 ].…”

Section: (Continued)mentioning

confidence: 97%

Assessment and management of breakthrough pain in cancer patients: Current approaches and emerging research

Hagen

Biondo²,

Stiles³

2008

Current Science Inc

View full text Add to dashboard Cite

Cancer pain is highly prevalent and often severe. Fortunately, most cancer pain can be readily managed, with up to 90% of patients responding well to standard interventions. However, breakthrough cancer pain-brief flares of severe pain superimposed on baseline pain-is common, difficult to manage, and often negatively impacts patients' quality of life. Breakthrough cancer pain is traditionally managed with oral, immediate-release opioids. However, because of its sudden onset and severity, oral opioids often fall short of providing adequate control. Research into novel approaches to pain management has identified several innovative strategies for this difficult cancer pain problem. We describe current approaches to assess, define, characterize, and treat breakthrough cancer pain, and summarize recent clinical research on novel agents, novel routes of drug delivery, and other advances in its management.

show abstract

“…Early attempts to use these drugs to relieve pain from nonmalignant causes (33,34) must also be viewed with reservation. A systematic review of breakthrough noncancer pain concludes that there is no evidence base for the use of immediate-release opioids in this setting (35).…”

Section: Discussionmentioning

confidence: 99%

Fentanyl for the Treatment of Tumor-Related Breakthrough Pain

Bornemann‐Cimenti

Wejbora²,

Szilagyi³

et al. 2013

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

SUMMARYBackground: Breakthrough cancer pain (BTCP) is common among cancer patients and markedly lowers their quality of life. The treatment for BTCP episodes that is recommended in current guidelines involves extended-release formulations in combination with rapid-onset and shortacting opioids. In the past few years, several new preparations of fentanyl, an opioid with a very rapid onset, have been approved for this indication. Treating physicians need to be aware of the clinical differences between the newer fentanyl preparations and immediate-release opioids.

show abstract

Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study

Cited by 87 publications

References 30 publications

Clinical Policy: Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department

Clinical Policy: Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department

Assessment and management of breakthrough pain in cancer patients: Current approaches and emerging research

Fentanyl for the Treatment of Tumor-Related Breakthrough Pain

Contact Info

Product

Resources

About